ERBB2 and non-small cell lung carcinoma: Although T-DXd is currently approved for HER2-mutant lung cancer in the later-line setting (CSCO, 2024), this case highlights its potential in perioperative management for HER2 exon 20 insertion-mutant NSCLC, an aggressive subtype.